Wells Fargo
FULC icon

Wells Fargo’s Fulcrum Therapeutics FULC Stock Holding History

Wells Fargo’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$182K Buy
49,696
+27,145
+120% +$165K ﹤0.01% 5252
2026
Q1 		$173K Sell
22,551
-143,844
-86% -$1.33M ﹤0.01% 4788
2025
Q4 		$1.88M Buy
166,395
+133,888
+412% +$1.36M ﹤0.01% 3492
2025
Q3 		$299K Sell
32,507
-1,241
-4% -$8.98K ﹤0.01% 4687
2025
Q2 		$232K Buy
33,748
+3,228
+11% +$17.3K ﹤0.01% 4687
2025
Q1 		$87.9K Sell
30,520
-3,744
-11% -$13.8K ﹤0.01% 5164
2024
Q4 		$161K Buy
34,264
+8,761
+34% +$32.3K ﹤0.01% 4918
2024
Q3 		$91K Buy
25,503
+383
+2% +$2.84K ﹤0.01% 5074
2024
Q2 		$156K Buy
25,120
+24,733
+6,391% +$187K ﹤0.01% 4672
2024
Q1 		$3.65K Buy
387
+6
+2% +$54 ﹤0.01% 5943
2023
Q4 		$2.57K Buy
381
+20
+6% +$89 ﹤0.01% 6061
2023
Q3 		$1.6K Sell
361
-604
-63% -$2.64K ﹤0.01% 6127
2023
Q2 		$3.19K Sell
965
-8,801
-90% -$25.9K ﹤0.01% 6150
2023
Q1 		$27.8K Buy
9,766
+6,571
+206% +$58.9K ﹤0.01% 5490
2022
Q4 		$23.3K Sell
3,195
-2,358
-42% -$15.4K ﹤0.01% 5195
2022
Q3 		$45K Sell
5,553
-317
-5% -$2.27K ﹤0.01% 5008
2022
Q2 		$29K Sell
5,870
-8,183
-58% -$80K ﹤0.01% 5273
2022
Q1 		$332K Sell
14,053
-8,765
-38% -$124K ﹤0.01% 4692
2021
Q4 		$403K Buy
22,818
+16,959
+289% +$336K ﹤0.01% 4831
2021
Q3 		$165K Sell
5,859
-2,073
-26% -$39.3K ﹤0.01% 5183
2021
Q2 		$83K Sell
7,932
-1,417
-15% -$14.3K ﹤0.01% 5364
2021
Q1 		$110K Sell
9,349
-9,483
-50% -$117K ﹤0.01% 5436
2020
Q4 		$221K Buy
18,832
+3,992
+27% +$45.1K ﹤0.01% 5030
2020
Q3 		$117K Sell
14,840
-458
-3% -$5.51K ﹤0.01% 5196
2020
Q2 		$279K Buy
15,298
+6,176
+68% +$97.2K ﹤0.01% 4704
2020
Q1 		$109K Buy
9,122
+7,129
+358% +$114K ﹤0.01% 5018
2019
Q4 		$33K Buy
1,993
+1,629
+448% +$15.6K ﹤0.01% 5625
2019
Q3 		$2K Buy
+364
New +$4.03K ﹤0.01% 6191

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wells Fargo's FULC Position: Q2 2026 in Review

Wells Fargo increased its Fulcrum Therapeutics (FULC) stake by 120% in Q2 2026, buying an estimated $165K and bringing the position to 49,696 shares worth $182K. The position accounts for ﹤0.01% of the portfolio, ranked #5252.

Wells Fargo first reported a position in FULC in Q3 2019 and has held it in 28 quarters since. The position peaked at $1.88M in Q4 2025. 155 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • Wells Fargo held 49,696 shares of Fulcrum Therapeutics worth $182K as of Q2 2026.
  • Wells Fargo bought 27,145 Fulcrum Therapeutics shares in Q2 2026, an estimated $165K.
  • Fulcrum Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #5252 holding.
  • Wells Fargo first reported a position in Fulcrum Therapeutics in Q3 2019 and has held it in 28 quarters since.
  • Wells Fargo's Fulcrum Therapeutics position peaked at $1.88M in Q4 2025.
  • 155 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.